November 7, 2011 - Pharmasset Inc (VRUS) is jumping again this morning after the INHX upgrades we've been seeing. Canaccord says VRUS is a buy with a 2012 price target of $126. VRUS stock is trading at $74.51, Up 8.7%
Recent News
Pharmasset, Inc. (Nasdaq:VRUS) and Bristol-Myers Squibb Company (NYSE:BMY) announced today the addition of four treatment arms to the ongoing Phase IIa trial evaluating the combination of Pharmasset’s PSI-7977, a nucleotide polymerase inhibitor, and Bristol-Myers Squibb Company’s (NYSE:BMY - News) daclatasvir (BMS-790052), an investigational NS5A replication complex inhibitor, for the treatment of chronic hepatitis C (HCV). This trial is the result of a clinical collaboration agreement between Pharmasset and Bristol-Myers Squibb announced in January 2011.
